Published in J Nanobiotechnology on April 26, 2014
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol (2015) 0.90
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics (2016) 0.83
Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget (2016) 0.83
Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques. J Virol (2016) 0.81
Modulation of Innate Immune Responses via Covalently Linked TLR Agonists. ACS Cent Sci (2015) 0.76
Particle-based platforms for malaria vaccines. Vaccine (2015) 0.76
Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J Control Release (2016) 0.75
Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica. Vaccine (2017) 0.75
Immune Response Modulation of Conjugated Agonists with Changing Linker Length. ACS Chem Biol (2016) 0.75
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
TLR signaling. Semin Immunol (2007) 8.16
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release (2012) 3.41
Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell (2006) 3.23
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol (2010) 2.10
Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog (2008) 1.83
Areas of molecules in membranes consisting of mixtures. Biophys J (2005) 1.81
New insights into the regulation of TLR signaling. J Leukoc Biol (2006) 1.68
BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway. Nat Commun (2012) 1.62
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42
Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev (2012) 1.39
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol (2006) 1.31
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun (2008) 1.13
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood (2010) 1.07
T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One (2011) 1.04
Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res (2014) 1.04
TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum Genet (2005) 1.01
Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie (2012) 0.98
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Local tolerance of subcutaneous injections. J Pharm Pharmacol (1996) 0.95
Development of a topically active imiquimod formulation. Pharm Dev Technol (1999) 0.92
Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation. Small (2013) 0.92
Characterization of TLR4 agonist effects on alhydrogel® sedimentation: a novel application of laser scattering optical profiling. J Pharm Sci (2012) 0.91
In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf B Biointerfaces (2013) 0.91
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstet Gynecol (2011) 0.89
Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol (2006) 0.89
Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol (2012) 0.85
Predicting hydrophilic drug encapsulation inside unilamellar liposomes. Int J Pharm (2011) 0.80
Synergy between vitamin D(3) and Toll-like receptor agonists regulates human dendritic cell response during maturation. Clin Dev Immunol (2013) 0.79
Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants. Bioconjug Chem (2013) 0.78
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A (2002) 1.65
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Zoonotic Leprosy in the Southeastern United States. Emerg Infect Dis (2015) 1.48
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol (2007) 1.45
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol (2006) 1.43
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis (2010) 1.28
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine (2002) 1.28
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun (2006) 1.23
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis (2011) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop (2003) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin Vaccine Immunol (2010) 1.19
Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun (2008) 1.18
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry (2002) 1.16
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice. Clin Diagn Lab Immunol (2004) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem (2010) 1.12
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006) 1.12
ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clin Vaccine Immunol (2006) 1.11
Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun (2006) 1.09
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine (2007) 1.09
Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz (2012) 1.08
Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy. J Clin Microbiol (2013) 1.06
Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces (2008) 1.06
HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine (2013) 1.03
The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2011) 1.03
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol (2013) 1.03
KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol (2011) 1.01
Cloning of the gene encoding a protective Mycobacterium tuberculosis secreted protein detected in vivo during the initial phases of the infectious process. J Immunol (2005) 1.01
Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem (2002) 1.00
Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol (2012) 1.00
Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. FEMS Immunol Med Microbiol (2009) 0.99
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev (2003) 0.99
Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene (2002) 0.98
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine (2010) 0.98
Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis (2011) 0.98
Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun (2011) 0.97
Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol (2008) 0.97
Prostein expression is highly restricted to normal and malignant prostate tissues. Prostate (2004) 0.97
Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol (2010) 0.97
Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol (2008) 0.96
Role of adjuvants in modeling the immune response. Curr Opin HIV AIDS (2010) 0.96
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine (2011) 0.96
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ. Eur J Immunol (2014) 0.96
Development of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technology. BMC Infect Dis (2013) 0.95
Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotes. Infect Immun (2010) 0.95
Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon. Infect Immun (2009) 0.94